patent.fyi
Applications  /  US 2026/0356926
United States Patent Application Publication

US 2026/0356926 A1

Published
Nov 12, 2026
Filed
Aug 22, 2025
Earliest date on the face
Apr 18, 2025
Classification
C07K 16/18
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Ankyrin repeats bind Gremlin2

What ifWhat if an engineered ankyrin repeat protein formed the Gremlin2-binding surface?
Claim language“a heavy chain variable region”

Solvent-exposed residues on tandem ankyrin repeats form the binding surface. A receptor competition assay selects repeat proteins that occupy the Gremlin2 contact surface used by TGF-β receptor 1.

1.1Reselected heavy chain CDR2

What ifWhat if heavy chain CDR2 had a different amino acid sequence selected for Gremlin2 binding?
Claim language“as set forth in SEQ ID NO. 2”

A yeast display library varies heavy chain CDR2 while holding the other five CDRs fixed. Screening identifies sequence variants that bind Gremlin2, and a receptor competition assay measures whether the resulting antibodies block receptor binding.

1.2Single domain supplies binding

What ifWhat if a single-domain antibody used three loops on one immunoglobulin domain to supply all Gremlin2 contacts without a separate light chain?
Claim language“the light chain”

A compact immunoglobulin framework positions three binding loops on one polypeptide. Selection for Gremlin2 binding followed by receptor competition screening identifies domains that block the Gremlin2–receptor interaction.

1.2Fibronectin domain supplies binding

What ifWhat if a fibronectin type III domain formed the Gremlin2-binding surface in place of the light chain variable region?
Claim language“a light chain variable region”

Three exposed loops on the fibronectin type III domain form an autonomous binding surface. Display selection enriches loop variants that bind Gremlin2, and receptor competition measurements identify variants that obstruct the receptor contact surface.

1.2Reselected light chain CDR3

What ifWhat if light chain CDR3 had a different amino acid sequence selected for receptor competition?
Claim language“as set forth in SEQ ID NO. 6”

A display library pairs a fixed heavy chain with light chains that differ in CDR3 sequence. Gremlin2 binding and receptor competition assays identify alternative CDR3 sequences that retain the interaction-blocking function.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Antibody column for culture fluid analysis

The paired heavy and light chains form a capture antibody for measuring gremlin 2 in conditioned cell culture fluid. The antibody is immobilized through its Fc region on protein G agarose in a small flow-through column. Clarified culture fluid passes through the column, and a wash removes unbound material. The captured protein is eluted and quantified by liquid chromatography with mass spectrometry using gremlin 2 reference samples.

Component substitution

Kappa domain substitution in the light chain

A human kappa constant domain replaces a lambda constant domain in a light-chain construct carrying the three specified light-chain binding loops. The kappa domain joins directly to the carboxyl terminus of the light-chain variable region, and the resulting light chain is coexpressed with the heavy chain carrying the three specified heavy-chain binding loops. Nonreducing electrophoresis checks chain assembly, and a receptor competition assay measures inhibition of gremlin 2 binding.

Parameter or scale variation

Miniaturized receptor competition assay

A 384-well plate carries immobilized extracellular domains of transforming growth factor beta receptor 1. Each well receives a 20 µL mixture of labeled gremlin 2 and antibody after a 30-minute preincubation, with eight antibody concentrations spaced threefold apart. After a 60-minute binding step, the plate is washed and the retained label is measured. Wells containing gremlin 2 alone provide the reference signal for fractional inhibition.

Combination with existing systems

Antibody dosing in perfused lung cultures

A two-channel microfluidic culture device holds lung epithelial cells and lung fibroblasts on opposite sides of a porous membrane. A pump introduces gremlin 2 and the paired-chain antibody into the fibroblast channel through a fluid mixer upstream of the culture chamber. Imaging measures deposited collagen in the fibroblast layer. Parallel channels receiving gremlin 2 alone provide a reference for the collagen response.

Receptor competition on a plasmon sensor

A surface plasmon resonance instrument uses a flow cell carrying the immobilized extracellular domain of transforming growth factor beta receptor 1 and a reference flow cell prepared without receptor. A fixed concentration of gremlin 2 is mixed with serial dilutions of the paired-chain antibody and injected over both cells at the same flow rate. The instrument subtracts the reference signal and compares the receptor-channel response with the response from gremlin 2 alone. The resulting concentration series gives a receptor competition curve.

Automated or data-driven variant

Automated selection of antibody framework pairs

Software inserts the three heavy-chain binding loops and three light-chain binding loops into candidate human variable-region frameworks and enumerates heavy and light framework pairings. A liquid handler combines the corresponding expression plasmids in individual wells of a mammalian cell culture plate. Plate measurements report secreted antibody concentration and inhibition of gremlin 2 binding to the receptor. Software ranks the pairs by inhibition at a matched antibody concentration.

Specific version of a part

Heavy chain with IgG1 constant region

The heavy chain variable region contains CDR1, CDR2, and CDR3 from SEQ ID NO. 1, 2, and 3, respectively. An IgG1 constant region supplies the CH1, hinge, CH2, and CH3 segments for assembly with the corresponding light chain.

Kappa light chain assembly

The light chain variable region contains CDR1, CDR2, and CDR3 from SEQ ID NO. 4, 5, and 6, respectively. A kappa constant domain fused to the variable region pairs with the CH1 domain of the corresponding heavy chain.

Light chain with secretion signal

An expression cassette encodes a cleavable secretion signal upstream of the light chain containing the three specified CDRs. The signal directs the nascent light chain into the endoplasmic reticulum and is cleaved during processing before secretion of the assembled antibody.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2022/0348652 A1
Published
Nov 3, 2022
Filed
Apr 22, 2022
Class
C07K 16/2803
Document BUS 2023/0037864 A1
Published
Feb 9, 2023
Filed
Jun 28, 2022
Class
C07K 16/10
Claim 1
Document A
Document B
1.1the neutralizing antibody against pulmonary fibrosis consists of a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region comprising a heavy chain complementary-determining region 1 (CDR1) as set forth in SEQ ID NO. 1, a heavy chain complementary-determining region 2 (CDR2) as set forth in SEQ ID NO. 2, and a heavy chain complementary-determining region 3 (CDR3) as set forth in SEQ ID NO. 3
A recombinant antibody or a fragment thereof, comprising a variable light chain (VL) domain and a variable heavy chain (VH) domain, wherein the VL domain comprises a first light chain complementarity determining region (CDR-L1), a second light chain CDR (CDR-L2) and a third light chain CDR (CDR-L3), and the VH domain comprises a first heavy chain CDR (CDR-H1), a second heavy chain CDR (CDR-H2) and a third heavy chain CDR (CDR-H3), wherein the CDR-L1, CDR-L2, CDR-L3, CDR-H1, C
A · US 2022/0348652 A1 · claim 1
TABLE 2 Amino acid sequences of the VL and VH domains of the recombinant scFv SEQ ID Domain Amino acid sequence NO VL MDAMKRGLCCVLLLCGAVFVSPSASNIVLTQSPKS 6 MSMSVGERVTLSCKASENVGTYVSWYQQKPKQSPK LLIYGTFNRYTGVPDRFTGSGSATDFTLTISSVQA EDLADYHCGQSYNYPFTFGSGTKLEIK VH QVQLQQSGAELARPGTSVKMSCKASGYTFTNYMMH 7 WIKQRPGQGLEWIGYINPSTGYTNYNQKFKDKATL TADKSSSTAYVQLNILTSEDSAVYYCATSTLITGD YWGQGTTLTVSSKGQDNSAG * The CDR sequences were marked in boldface, including three CDRs (i.e., CDR-L1, CDR-L2 an
B · US 2023/0037864 A1 · ¶
1.2the light chain comprises a light chain variable region comprising a light chain CDR1 as set forth in SEQ ID NO. 4, a light chain CDR2 as set forth in SEQ ID NO. 5, and a light chain CDR3 as set forth in SEQ ID NO. 6.
A recombinant antibody comprising a light chain variable (VL) domain and a heavy chain variable (VH) domain, wherein the VL domain comprises a first light chain complementarity determining region (CDR-L1), a second light chain CDR (CDR-L2) and a third light chain CDR (CDR-L3), and the VH domain comprises a first heavy chain CDR (CDR-H1), a second heavy chain CDR (CDR-H2) and a third heavy chain CDR (CDR-H3), wherein the CDR-L1, CDR-L2 and CDR-L3 respectively comprise the amin
B · US 2023/0037864 A1 · claim 1

An empty cell means only that no passage was reproduced there.

Statements in these documents
Accordingly, there remains a need to develop a novel antibody that specifically binds to CD47 and blocks the signaling of CD47 and SIRPα.
A · US 2022/0348652 A1 · ¶ 4
More particularly, the present disclosure relates to recombinant antibodies and uses thereof in the treatment of CD47-associated diseases, e.g., cancers.
A · US 2022/0348652 A1 · ¶ 2
In view of the foregoing, there exists in the related art a need for a novel agent for treating PEDV infection so as to minimize the impact of PEDV on swine health and production.
B · US 2023/0037864 A1 · ¶ 5
As embodied and broadly described herein, one aspect of the disclosure is directed to a recombinant antibody for the diagnosis and/or treatment of PEDV infection.
B · US 2023/0037864 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0356926 A1, claim 1, first published 2026-11-20T08:53:13-05:00, https://patent.fyi/US20260356926/, SHA-256 db43acf69ff770ab95b432ad44a0f6d7741997eabb79d2fcd549d1120eb2025f
First published
Permanent addresshttps://patent.fyi/US20260356926/
Content fingerprint (SHA-256)db43acf69ff770ab95b432ad44a0f6d7741997eabb79d2fcd549d1120eb2025f
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi